Abstract：Oxcarbazepine is a new antiepileptic drug. The results of clinical trials suggest that oxcarbazepine is well tolerated and has less drug interactions. It is being used more and more widely in clinical practice, but its adverse effects should not be ignored. The most common adverse effects of oxcarbazepine are usually related to the central nervous system and digestive system, including fatigue, drowsiness, diplopia, dizziness, nausea and vomit. The common skin adverse reaction is rash. Long-term use of oxcarbazepine may also cause hyponatremia. This article reviews the literature from China and overseas about the adverse effets of oxcarbazepine over the last 10 years in order to find information about rational clinical use of oxcarbazepine.
Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent[J]. Clin Ther, 2001, 23(5): 680-700, 645.
[2]
Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?[J]. Epilepsy Behav, 2004, 5(5): 627-635.
He N, Min FL, Shi YW, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles[J]. Seizure, 2012, 21(8): 614-618.
[5]
Chung WH, Hung SI, Chen YT. Genetic predisposition of lifethreatening antiepileptic-induced skin reactions[J]. Expert Opin Drug Saf, 2010, 9(1): 15-21.
[6]
Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine[J]. Personal Med, 2005, 2(3): 225-237.
Le Louet H, Thomas L, Babai S. DRESS: is oxcarbazepine safer than carbamazepine? An analysis of the French Pharmacovigilance database[J]. Eur J Neurol, 2008, 15(5): e43.
[10]
Knudsen JF, Flowers CM, Kortepeter C, et al. Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review[J]. Pediatr Neurol, 2007, 37(2): 134-137.
[11]
Bourgeois BF, D'Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience[J]. Epilepsy Behav, 2005, 7(3): 375-382.
[12]
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial[J]. Lancet, 2007, 369(9566): 1016- 1026.
[13]
Franzoni E, Gentile V, Pellicciari A, et al. Prospective study on long-term treatment with oxcarbazepine in pediatric epilepsy[J]. J Neurol, 2009, 256(9): 1527-1532.
Martinez W, Ingenito A, Blakeslee M, et al. Efficacy, safety, and tolerability of oxcarbazepine monotherapy[J]. Epilepsy Behav, 2006, 9(3): 448-456.
[16]
Striano S, Striano P, Di Nocera P, et al. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy[J]. Epilepsy Res, 2006, 69(2): 170-176.
[17]
Gros-Otero J, Gorrono-Echebarria M, Benitez-Herreros J. Bilateral acute anterior uveitis and anticonvulsant hypersensitivity syndrome[J]. Arch Soc Esp Oftalmol, 2010, 85(11): 376-377.
[18]
Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy[J]. Epilepsy Res, 1989, 3(1): 70-76.
[19]
Kwon S, Lee S, Hyun M, et al. The potential for QT prolongation by antiepileptic drugs in children[J]. Pediatr Neurol, 2004, 30(2): 99-101.
[20]
Emeksiz HC, Serdaroglu A, Biberoglu G, et al. Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs[J]. Seizure, 2013, 22(2): 124-127.
[21]
Belcastro V, Striano P, Gorgone G, et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs[J]. Epilepsia, 2010, 51(2): 274-279.
[22]
Calamaras MR, Stowe ZN, Newport DJ. Pancytopenia associated with the introduction of oxcarbazepine[J]. J Clin Psychopharmacol, 2007, 27(2): 217-218.
[23]
Milia A, Pilia G, Mascia MG, et al. Oxcarbazepine-induced leukopenia[J]. J Neuropsychiatry Clin Neurosci, 2008, 20(4): 502-503.
[24]
Pratoomsri W, Yatham LN, Bond DJ, et al. Oxcarbazepine in the treatment of bipolar disorder: a review[J]. Can J Psychiatry, 2006, 51(8): 540-545.
[25]
Rey E, Bulteau C, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy[J]. J Clin Pharmacol, 2004, 44(11): 1290- 1300.
Garoufi A, Koemtzidou E, Katsarou E, et al. Lipid profile and thyroid hormone concentrations in children with epilepsy treated with oxcarbazepine monotherapy: a prospective long-term study[J]. Eur J Neurol, 2014, 21(1): 118-123.
[28]
Cansu A, Serdaroglu A, Camurdan O, et al. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate[J]. Epilepsia, 2006, 47(11): 1855- 1859.
[29]
Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures[J]. Pediatr Neurol, 2005, 33(5): 337-344.
[30]
Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia[J]. Seizure, 2014, 23(3): 208-212.
[31]
Lin CH, Lu CH, Wang FJ, et al. Risk factors of oxcarbazepineinduced hyponatremia in patients with epilepsy[J]. Clin Neuropharmacol, 2010, 33(6): 293-296.
[32]
Asconape JJ. Some common issues in the use of antiepileptic drugs[J]. Semin Neurol, 2002, 22(1): 27-39.
[33]
Wade JF, Dang CV, Nelson L, et al. Emergent complications of the newer anticonvulsants[J]. J Emerg Med, 2010, 38(2): 231- 237.
[34]
Milovan D, Almeida L, Romach MK, et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers[J]. Epilepsy Behav, 2010, 18(4): 366-373.
[35]
Park S, Lee H, Jung D, et al. Long-term cognitive effects of oxcarbazepine monotherapy in epilepsy patients[J]. J Neurol Sci, 2005, 238(S1): S138.
[36]
Araujo IM, Ambrosio AF, Leal EC, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093[J]. Epilepsia, 2004, 45(12): 1498-1505.
[37]
Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy[J]. Curr Med Res Opin, 2005, 21(5): 693-701.
Veerapandiyan A, Singh P, Mikati MA. Possible induction of West syndrome by oxcarbazepine therapy in a patient with complex partial seizures[J]. Epileptic Disord, 2012, 14(1): 99- 103.
[42]
Hahn A, Fischenbeck A, Stephani U. Induction of epileptic negative myoclonus by oxcarbazepine in symptomatic epilepsy[J]. Epileptic Disord, 2004, 6(4): 271-274.
[43]
Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs[J]. Pediatr Neurol, 2005, 33(4): 227-234.
Rallis E, Theodoridis A, Moussatou V, et al. Oxcarbazepineinduced localized penile edema[J]. J Dtsch Dermatol Ges, 2005, 3(10): 786-787.
[46]
Herguner MO, Incecik F, Altunbasak S. Oxcarbazepine-induced tardive dyskinesia: a rare adverser eaction[J]. J Pediatr Neurosci, 2010, 5(1): 85-86.
[47]
Linnet K, Steentoft A, Simonsen KW, et al. An oxcarbazepinerelated fatality with an overview of 26 oxcarbazepine postmortem cases[J]. Forensic Sci Int, 2008, 177(2-3): 248-251.
